Comprehensive Assessment of Interconnection Between Brain Emotional Activity and Coronary Plaque Instability

Sponsor
Korea University Guro Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT04853511
Collaborator
(none)
200
1
34.5
5.8

Study Details

Study Description

Brief Summary

Emotional stress is associated with future cardiovascular events. However, the biological interconnection between brain emotional neural activity and acute plaque instability is not fully understood. Optical coherence tomography-Fluorescence Lifetime (OCT-FLIM) dual modal intravascular imaging is a novel technique that enables comprehensive assessment of structural and biochemical characteristics of coronary atheroma and estimates the level of plaque instability. 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT) enables simultaneous estimation of multi-system activities including emotional stress, arterial inflammation, and hematopoiesis. The present study aims to prospectively investigate mechanistic linkage between coronary plaque instability, stress-associated neurobiological activity, and macrophage hematopoiesis using OCT-FLIM and 18F-FDG PET/CT imaging assessment.

Condition or Disease Intervention/Treatment Phase
  • Device: OCT-FLIM (optical coherence tomography-fluorescence life time)

Detailed Description

Thirty two patients with multivessel coronary artery disease (including both stable angina and acute coronary syndrome), who have at least one severe obstructive lesion (>70% diameter stenosis) that is considered suitable for percutaneous coronary intervention (PCI), will be included in the study.

Structural/biochemical characteristics of coronary culprit plaque (with or without mild to moderate stenotic non-culprit plaque) will be assessed comprehensively using OCT-FLIM dual modal intravascular imaging.

After coronary revascularization with PCI, subjects will undergo serial 18F-FDG-PET/CT molecular imaging at baseline admission and 6-month follow-up to measure PET signal activities at target tissues including amygdala, carotid artery, aorta, bone marrow, and spleen.

Correlation between OCT-FLIM parameters and baseline PET signals will be assessed to provide insight into the mechanistic linkage between multi-system metabolic activities and coronary plaque instability. Serial PET/CT imaging after 6 month will enable estimation of natural course of multi-system PET signal activities according to different levels of coronary plaque instability.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
200 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Biological Interconnection Between Stress-associated Neurobiological Activity and Atherosclerotic Plaque Instability: A Prospective Cohort Study With OCT-FLIM Dual-modal Intravascular Imaging and Serial 18F-FDG-PET/CT Assessment
Actual Study Start Date :
Feb 14, 2022
Anticipated Primary Completion Date :
Dec 31, 2023
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
OCT-FLIM dual modal intravascular imaging with serial 18F-FDG-PET/CT assessment

Group of patients undergoing PCI with comprehensive assessment of coronary plaque with OCT-FLIM dual modal intravascular imaging followed by serial 18F-FDG-PET/CT imaging

Device: OCT-FLIM (optical coherence tomography-fluorescence life time)
comprehensive assessment of coronary plaque with OCT-FLIM dual modal intravascular catheter imaging followed by serial 18F-FDG-PET/CT imaging
Other Names:
  • 18F-FDG-PET/CT (positron emission tomography-computed tomography)
  • Outcome Measures

    Primary Outcome Measures

    1. Baseline amygdalar activity (Stress-associated neurobiological activity) [Baseline (within index admission)]

      Amygdalar target-to-background ratio (TBR) = Amygdalar standardized uptake value (SUV) / Temporal lobe SUV

    Secondary Outcome Measures

    1. Baseline carotid inflammation (arterial atherosclerotic inflammation) [Baseline (within index admission)]

      Carotid TBR = Carotid SUV / Jugular vein SUV

    2. Baseline aortic inflammation (arterial atherosclerotic inflammation) [Baseline (within index admission)]

      Aorta TBR = Aorta SUV / Jugular vein SUV

    3. Baseline bone marrow hematopoiesis (hematopoietic activity) [Baseline (within index admission)]

      Bone marrow TBR = Bone marrow SUV / Jugular vein SUV

    4. Baseline splenic hematopoiesis (hematopoietic activity) [Baseline (within index admission)]

      Spleen TBR = Spleen SUV / Jugular vein SUV

    5. Coronary plaque composition estimated by OCT-FLIM [Baseline (day 1)]

      Fluorescence Lifetime values that predicts detailed coronary plaque composition

    Other Outcome Measures

    1. Follow-up amygdalar activity (Stress-associated neurobiological activity) [6-month follow-up]

      Amygdalar TBR = Amygdalar SUV / Temporal lobe SUV

    2. Follow-up carotid inflammation (arterial atherosclerotic inflammation) [6-month follow-up]

      Carotid TBR = Carotid SUV / Jugular vein SUV

    3. Follow-up aortic inflammation (arterial atherosclerotic inflammation) [6-month follow-up]

      Aorta TBR = Aorta SUV / Jugular vein SUV

    4. Follow-up bone marrow hematopoiesis (hematopoietic activity) [6-month follow-up]

      Bone marrow TBR = Bone marrow SUV / Jugular vein SUV

    5. Follow-up splenic hematopoiesis (hematopoietic activity) [6-month follow-up]

      Spleen TBR = Spleen SUV / Jugular vein SUV

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years to 75 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Age: greater than 20, less than 75

    • Patients with severe coronary atherosclerosis (diameter stenosis >70%) requiring coronary revascularization

    • Reference vessel diameter: between 2.5 and 4.0 mm

    • Obtained informed consent from voluntary participants before study enrollment

    Exclusion Criteria:
    • Complex coronary lesion (ostial lesion, unprotected left main lesion, chronic total occlusion, grafted vessels, etc)

    • Reference vessel diameter: less than 2.5 mm, greater than 4.0 mm

    • Coronary lesion with heavy calcification

    • Hemodynamic instability during coronary intervention

    • Contraindication to antithrombotic therapy

    • Chronic renal insufficiency (Serum creatinine >2.0mg/dL)

    • Severe liver dysfunction (aspartate transaminase or alanine transferase > 5 times of upper normal limit)

    • Pregnancy or potential pregnancy

    • Life expectancy less than 1 year

    • Patient refused to sign the informed consent at enrollment

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Korea University Guro Hospital Seoul Korea, Republic of 08308

    Sponsors and Collaborators

    • Korea University Guro Hospital

    Investigators

    • Principal Investigator: Jin Won Kim, MD, PhD, Korea University Guro Hospital
    • Study Director: Dong Oh Kang, MD, PhD, Korea University Guro Hospital
    • Study Director: Sun Won Kim, MD, PhD, Korea University
    • Study Director: Hongki Yoo, PhD, Korea Advanced Institute of Science and Technology

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Jin Won Kim, Principal Investigator, Korea University Guro Hospital
    ClinicalTrials.gov Identifier:
    NCT04853511
    Other Study ID Numbers:
    • SRFC-IT1501-05_a
    First Posted:
    Apr 21, 2021
    Last Update Posted:
    Aug 24, 2022
    Last Verified:
    Aug 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Jin Won Kim, Principal Investigator, Korea University Guro Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 24, 2022